about
Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primatesVaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycansStructural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 proteinThe Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like DomainsThe mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.Review: Capripoxvirus Diseases: Current Status and Opportunities for Control.New generation smallpox vaccines: a review of preclinical and clinical data.Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infectionNew classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in miceAntibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entryThe identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.Smallpox vaccines: targets of protective immunity.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsPolyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge.Smallpox subunit vaccine produced in Planta confers protection in mice.Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection.Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in miceAdjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challengesImmunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigensVaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challengeHumoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations.Characterizing monkeypox virus specific CD8+ T cell epitopes in rhesus macaques.Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.Antibody responses to vaccinia membrane proteins after smallpox vaccination.CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.Correlates of protective immunity in poxvirus infection: where does antibody stand?Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complementMacaque models of human infectious disease.
P2860
Q27325586-46577F61-1AC5-41AA-B27E-DCC075D55EF0Q27488704-9EE6FF40-540D-4518-89E6-6A67CAF7C7C8Q27647102-E377D56D-B538-4BB6-8E91-F11C0F5E58AFQ27658759-A412062B-5691-43A7-AC01-917B02A1CC5DQ30223108-96F61087-92B8-435C-AAFE-4B816ACCD874Q30252040-89B57DA3-3BD4-462E-B466-DE0342195711Q31147081-FFE6AA40-5F27-4D34-BE61-8C4E96DF4FB5Q33302672-316E5A10-3CFE-4CE7-A1B0-7AC7C579FDEEQ33508318-584EBCB3-8CD9-4B34-AF42-EAECB1E89813Q33905188-A2A38835-53F3-427F-83B0-D3C9A90DC98CQ33936717-5BAD4E2B-9AE3-42AF-9F40-081B1B67156CQ34126697-94B0D746-220A-4192-80E6-843454C51FBEQ34259469-5B3FB24B-CE93-41E7-8D62-DF21043F5993Q34288498-7AEA6166-E69B-426A-A829-2DD9A72DE2BCQ34289866-25C01077-0443-4E79-B4A6-51E94E63E649Q34470311-FD6C84E7-45CB-4714-A094-B47E16E9F36FQ34502997-51110B3C-96B0-41B4-9916-96F71F3F6B8CQ34780607-7844DF13-8D26-4967-BCE2-E188D142B18BQ34910424-CC1EBE85-A88D-4397-9C24-4EA36693F507Q35152092-2B23E8F7-A8BD-4D92-8751-527FF3F7E7F1Q35192889-8D3FBD8D-1E57-4640-928E-6C54FBCE6BBFQ35339702-39DA5026-162D-4AEF-B6A3-A7A10735605FQ35667240-822E986D-22CE-44AE-AA7F-139A2ED24ED9Q35800424-8BD462AB-690D-4FFC-B05D-5734F68FEAE5Q35830974-8E692E7A-B4CB-4ACE-BBB6-71489697D2AFQ35947780-EBF12375-4B82-4DDC-9BD9-29B303B7CBE6Q35951545-AF217AE5-898B-49A6-9FE2-2474C5468FF4Q36477717-8F903EBE-2287-4AB3-8A74-5D665A4D924AQ36498244-6E0C6306-C4B5-4C72-9157-96E7094600EAQ36559636-2F278E9B-6ADF-4A03-B8CB-BB691216F28CQ36631459-758A743B-01C5-4769-9A22-C98C7D7B9B83Q36747784-DCF304C7-20C6-45A0-81FE-1E4C8E056EBAQ36808703-A268E3F7-1081-4F8F-A7DF-E8AF2D245667Q36869365-121AA1AD-2F6D-4DF4-A31C-6A84717AE7A9Q36920299-ACE552E0-08A7-47B7-B61D-E1898FE26BB5Q36965655-3D59E44E-BF7E-4D00-8519-65A8AF5E2C5CQ37003207-16D8575B-C33C-4AB7-9CC1-FC20CD78F185Q37042331-657869D8-E3C8-480B-B4E1-5CE4952D093EQ37051617-8FC6AD4B-00E6-4BAF-8D60-6380A88ED201Q37103536-3BA89D45-8CCB-4B5B-958F-5840EE5B8A30
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Subunit recombinant vaccine protects against monkeypox.
@en
type
label
Subunit recombinant vaccine protects against monkeypox.
@en
prefLabel
Subunit recombinant vaccine protects against monkeypox.
@en
P2093
P50
P1476
Subunit recombinant vaccine protects against monkeypox.
@en
P2093
Christopher J Trindade
David Venzon
Genoveffa Franchini
Hana Golding
Irene Kalisz
Janie Parrino
Jay W Hooper
Jody Manischewitz
Lisa R King
Meredith Hassett
P304
P356
10.4049/JIMMUNOL.177.4.2552
P407
P577
2006-08-01T00:00:00Z